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Pioneering work in the 1970s led to the isolation and 
identification of mesenchymal stem/stromal cells (MSCs) 
[1, 2]; these cells are now considered to be a promising 
candidate for cell-based therapies, tissue engineering 
and regenerative medicine applications due to their 
multipotency, propensity to grow in vitro, promising 
efficacy data, ease of isolation and immune modulatory 
properties [3–7]. However, the effective transfer of human 
MSCs (hMSCs) into widespread clinical application will 
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Production of human mesenchymal stem cells for allogeneic cell therapies requires scalable, cost-
effective manufacturing processes. Microcarriers enable the culture of anchorage-dependent cells 
in stirred-tank bioreactors. However, no robust, transferable methodology for microcarrier selec-
tion exists, with studies providing little or no reason explaining why a microcarrier was employed. 
We systematically evaluated 13 microcarriers for human bone marrow-derived mesenchymal 
stem cells (hBM-MSCs) expansion from three donors to establish a reproducible and transferable 
methodology for microcarrier selection. Monolayer studies demonstrated input cell line variabil-
ity with respect to growth kinetics and metabolite flux. HBM-MSC1 underwent more cumulative 
population doublings over three passages in comparison to hBM-MSC2 and hBM-MSC3. In 
100 mL spinner flasks, agitated conditions were significantly better than static conditions, irrespec-
tive of donor, and relative microcarrier performance was identical where the same microcarriers 
outperformed others with respect to growth kinetics and metabolite flux. Relative growth kinet-
ics between donor cells on the microcarriers were the same as in the monolayer study. Plastic 
microcarriers were selected as the optimal microcarrier for hBM-MSC expansion. HBM-MSCs 
were successfully harvested and characterized, demonstrating hBM-MSC immunophenotype and 
differentiation capacity. This approach provides a systematic method for microcarrier selection, 
and the findings identify potentially significant bioprocessing implications for microcarrier-based 
allogeneic cell therapy manufacture.
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Table 1.  Properties of commercially available microcarriers
Microcarrier  Manufacturer  Diameter   Matrix  Average  Surface  Surface  Carrier porosity  Usage in 
    (µm)    density  coating  charge    this study
Mammalian protein-coated microcarriers
Collagen SoloHill Eng. 125–212 Polystyrene 1.02 Type I porcine None Non-porous  (Coll) 
 Inc.    collagen
Cultispher-G® Percell- 130–380 Type I 1.04 None None Macroporous  (CG) 
 Biolytica  porcine     (porosity: 50% pore 
   gelatin    size: 10–30 µm)
Cytodex 3TM GE Healthcare 141–211 Dextran 1.04 Type I porcine  None Non-porous  (Cyto3) 
     collagen
FACT III SoloHill Eng. 125–212 Polystyrene 1.02 Cationic Type I + Non-porous  (FACT) 
 Inc.    porcine collagen
SphereCol® Advanced 125–212 Polystyrene 1.03 Type I human None Non-porous  
 BioMatrix    collagen  
     (VitroCol®)
Recombinant protein-coated microcarriers
ProNectin® F SoloHill Eng.  125–212 Polystyrene 1.02 Recombinant None Non-porous  (Pro-F) 
 Inc.    fibronectin
Xeno-free microcarriers
Cytodex 1TM GE Healthcare 147–248 Dextran 1.03 DEAE + Non-porous  (Cyto1)
Cytopore 1  GE Healthcare 200–280 Cotton 1.03 DEAE + Micro/Macroporous  
and 2TM   cellulose    (porosity: > 90%  
       pore size: 30 µm)
Enhanced  Corning 125–212 Polystyrene 1.02 CellBIND® None Non-porous  (EA) 
Attachment
Glass SoloHill Eng.  125–212 Polystyrene 1.02 High silica glass None Non-porous  
 Inc.
Hillex® CT SoloHill Eng.  90–212 Polystyrene 1.12 Cationic + Non-porous  
 Inc.    trimethyl  
     ammonium
Hillex® SoloHill Eng.  160–180 Dextran 1.11 Cationic + Non-porous  (Hillex) 
 Inc.    trimethyl  
     ammonium
MicroHexTM Nunc Side-length:  Polystyrene 1.05 NunclonTM Not Non-porous  (MHex) 
  125 µm   surface specified 
  Thickness:  
  25 µm
Plastic SoloHill Eng.  125–212 Polystyrene 1.02 None None Non-porous  (Plas) 
 Inc.
Plastic Plus SoloHill Eng.  125–212 Polystyrene 1.02 None + Non-porous  (Pplus) 
 Inc.
PVA Loughborough  100–220 PVA 1.03 None None Non-porous  (PVA) 
 University
Synthemax II® Corning 125–212 Polystyrene 1.02 Synthemax II® None Non-porous  (Sy)
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scale manufacturing platforms to produce fully functional 
cells at the capacity required to meet clinical demand. 
Various expansion platforms have been considered for 
hMSCs, including traditional monolayer expansion sys-
tems such as T-flasks and cell factories [8, 9], hollow-fibre 
based bioreactor systems [10, 11] and microcarrier expan-
sion in stirred-tank bioreactors [12–14]. For a detailed 
review and comparison of the advantages and disadvan-
tages of various culture systems (and anchorage-depend-
ent cells in general), see recent reviews [15–17]. 
Microcarrier-based bioreactor systems benefit from a 
significantly larger surface area to volume ratio compared 
to monolayer culture as well as providing the additional 
advantages of process control, flexible operation (i.e. 
batch, fed-batch, perfusion), homogenous culture condi-
tions via impeller agitation, readily-accessible sampling 
for both medium and cell material and the ability to har-
vest in situ [17–21]. It is because of this that a significant 
amount of research is being conducted into these sys-
tems for both hMSCs [13, 22–25] as well as other anchor-
age-dependent cell types [26–28].
Without going into detail regarding the hMSC-micro-
carrier studies, as this is covered elsewhere [17, 19], it is 
worth noting that there have been many different types 
of microcarriers used, each with a different structure 
(i.e. solid bead, macroporous, enzymatically digestible), 
coatings (fibronectin, collagen, gelatin) and particle sizes. 
Despite many studies involving hMSCs and microcarrier 
culture investigating various aspects of the culture pro-
cess, there is no unified set of culture conditions for hMSC 
microcarrier expansion. This is in part understandable 
given inevitable differences arising due to donor varia-
tion as well as the relative infancy of the research, with 
the earliest successful MSC microcarrier expansion being 
reported only in 2007 [22].
The selection of the appropriate microcarrier is a 
fundamental component of microcarrier/stirred-tank bio-
reactor cell expansion. From a cell therapy processing 
perspective, it is expected that once selected, the micro-
carrier of choice will need to remain the same throughout, 
particularly during the later stages of clinical develop-
ment (Phase II and Phase III) at which point the process is 
‘locked in’. Any change at this point is likely to constitute 
a major change in the manufacturing process, requiring 
significant comparability testing and repeats of clinical 
trials. Therefore, it is of paramount importance that the 
optimal microcarrier is selected from the outset based on 
a stringent selection methodology. 
Much of the work conducted in the literature does not 
specify why or how a specific microcarrier was selected 
for expansion, nor is it clear if any strategy or procedure 
was put in place to identify the optimal microcarrier, or 
indeed outline the criteria for what the ‘ideal’ microcar-
rier should be. Given the significance this has on the 
entire cell therapy production process, it is surprising 
that no in-depth study has been performed comparing 
the various commercially available microcarriers. Schop 
and colleagues [23] conducted a microcarrier screen 
comparing nine different commercially available micro-
carriers (Cytodex-1 and -3, and all SoloHill microcarriers; 
Table  1), yet the study was limited to identifying the 
extent of cell attachment over an 18 h period as deter-
mined by the Alamar Blue assay. They found that Cyto-
dex-1 allowed for the greatest seeding efficiency, and as 
such, conducted further research with this microcarrier 
only. However this study did not take into account hMSC 
growth kinetics after 18 h, nor did it take into account 
other key issues such as the harvesting of cells from the 
microcarriers. 
Kehoe and colleagues performed a similar study 
which included an investigation of cell recoverability and 
found that whilst Cytodex-1 appeared to best facilitate 
cell growth, it was significantly lower with respect to cell 
recoverability in comparison with the SoloHill Collagen 
microcarrier [24]. Whilst the study does provide some 
interesting insights, the study appears truncated and 
has not been peer-reviewed. Moreover, the study used 
only one hMSC line and provides little detail as to how 
cell growth for the microcarrier screen was determined. 
Whilst there have been attempts to select an appropriate 
microcarrier, it is clear there is no robust, rigorous, trans-
ferable process for microcarrier selection.
This study systematically evaluates microcarriers for 
hBM-MSCs from three different donors, provides a set 
of key criteria which define the ‘ideal’ microcarrier and 
provides a reproducible and transferable methodology 




Human MSCs from three different healthy donors were 
isolated from bone-marrow aspirate obtained by Lon-
za (Lonza, Walkersville, USA) after the donor provided 
informed consent. The local Ethical Committee approved 
the use of the samples for research. The donors were 
selected on the basis of different ages, genders and 
 ethnicities which are as follows: hBM-MSC1 (20 years 
old, male, black), hBM-MSC2 (19 years old, female, black), 
hBM-MSC3 (24 years old, male, caucasian). The hBM-
MSCs were isolated on the basis of plastic adherence 
and cryopreserved at passage 1 at a density of 2 × 106 
cells/mL in 10% v/v dimethyl sulphoxide (DMSO) (Sigma 
Aldrich, UK) and 90% foetal bovine serum (FBS; Hyclone, 
Lot# RUF35869). The cells were expanded until passage 
3 at which point experimental work began. Cells were 
cultured in complete growth medium, which consisted 
of Dulbecco’s Modified Eagle Medium (DMEM; Lonza, 
UK) supplemented with 10% v/v foetal bovine serum 
4 © 2015 The Authors. Biotechnology Journal published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
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(FBS; Hyclone, Lot# RUF35869) and 2 mM ultraglutamine 
(Lonza, UK). 
Monolayer expansion of hBM-MSCs involved seeding 
T-flasks or plates at a density of 5000 cells/cm2 and then 
placed in a humidified CO2 controlled incubator at 37°C 
which had air supplemented with 5% CO2. A complete 
medium exchange was performed after 72  h of culture 
and cells were passaged upon reaching confluency (day 
6 of culture). Passaging involved washing the hBM-MSC 
monolayer with Ca2+ and Mg2+ free phosphate buffered 
saline (PBS; Lonza, UK) followed by an incubation step for 
5 min with trypsin (0.25%)/EDTA solution (Lonza, UK) to 
dissociate the cells from the surface of the tissue culture 
plastic. Complete growth medium was added to inacti-
vate the trypsin at the three-fold volume of the trypsin 
solution used for cell detachment. The cell suspension 
was then centrifuged at 220 g for 5 min at room tempera-
ture, the supernatant discarded and the remaining pellet 
re-suspended in an appropriate volume of culture medi-
um. The viable cell number was determined by using the 
Nucleocounter NC-3000 image cytometer (Chemometec, 
Denmark) following the manufacturer’s instructions. 
2.2    Microcarrier culture
All microcarrier cultures were performed in vessels or 
plates designed to avoid attachment of the cells to the 
plate or vessel surface. This was achieved in multi-well 
plates by using ultra-low attachment plates (Corning, UK), 
whilst spinner flask vessels were coated in Sigmacote 
(Sigma Aldrich, UK). Sigmacote was used to treat glass 
vessels to siliconize the surface thereby preventing cell 
attachment to the vessel surface. Sigmacote was applied 
to the entire vessel surface area and aspirated. Vessels 
were left overnight to dry in a fume hood and rinsed with 
distilled water after 24 h and autoclaved prior to use.
All microcarriers used in this investigation (Table 1) 
were prepared according to the manufacturer’s instruc-
tions. For all microcarrier cultures, after initial sterilization 
by autoclaving, the microcarriers were left in complete 
growth medium for at least 1 h in a humidified incubator 
at 37°C and 5% CO2 to allow for the conditioning of the 
microcarriers and thereby aiding cell attachment. After 
this period, the conditioning medium was aspirated, tak-
ing care to avoid aspirating microcarriers, and fresh, pre-
warmed growth medium was added to the volume. Cells 
were then inoculated at a seeding density of 6000 cells/
cm2, greater than the 5000  cells/cm2 seeding density 
for monolayer culture. This was done so as to take into 
account cell loss due to the lack of attachment to a micro-
carrier.
2.3    Spinner flask configuration
100 mL BellCo spinner flasks (BellCo, US), were used for 
all spinner flask experiments, with a 100 mL working vol-
ume and a vessel diameter (T) of 60 mm. Agitation was 
achieved by a magnetic horizontal stir bar and a vertical 
paddle (diameter, D = 50 mm). Spinner flasks were set up 
on a Bell-EnniumTM Compact five position magnetic stir-
rer platform (BellCo, US), maintained in a 37°C, humidified 
incubator which had air supplemented with 5% CO2.
In spinner flask cultures, after microcarrier inocula-
tion, the vessels were warmed to 37°C but not agitated for 
a period of 24 h, this was done to allow the cells to settle 
and attach to the microcarriers. At all times whilst in the 
incubator, a side-arm of the spinner flask was slightly 
loosened (half a turn of the cap) to allow for sufficient gas 
exchange. After the initial settling period, the vessels 
were agitated; the spinner flasks were placed onto the 
Bell-EnniumTM Compact five position magnetic stirrer 
platform which allowed for the controlled agitation of the 
spinner flask via a magnetic stirrer.
The agitation speed for the spinner flasks was set to 
NJS (the impeller speed at which the microcarriers are 
just suspended [18]), which was found to be 30 rpm for 
the spinner flasks on the Bell-EnniumTM platform. For a 
detailed discussion as to why this speed was selected, the 
reader is directed to our liter-scale stirred-tank expansion 
study [14]. 
Cell attachment in the spinner flask cultures was 
determined by taking supernatant samples one hour after 
inoculation to ascertain the numbers of unattached cells. 




To determine the metabolite concentration in the hBM-
MSC cultures, 1  mL of spent medium was aseptically 
transferred to an Eppendorf tube and then run on the Bio-
profile FLEX bioanalyser for analysis of glucose in mmol/L, 
lactate in mmol/L, and ammonium in mmol/L.
The specific metabolite consumption/production rate 















  ⋅ −− µ
where qmet= specific metabolite consumption rate, µ = 
specific growth rate (h-1), Cmet(t) and Cmet(0) = concentra-
tion of metabolite at the start and end of exponential 
growth phase respectively, Cx(0) = cell number at the end 
of exponential growth phase and t = time (h).
The WST-1 assay (Roche, UK) was used to determine 
the metabolic activity of viable cells; a colorimetric test, 
the principle of the assay is the reduction of WST-1 by 
viable cells, producing a soluble and visible formazan salt 
which can be measured using an ELx800 plate reader 
(Invitrogen, UK). 
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2.5    Flow cytometry
Immunophenotypic analysis of the hBM-MSCs was deter-
mined by flow cytometry. This was performed using the 
Quanta SC flow cytometer with excitation at 488 nm. Cells 
were prepared for analysis following enzymatic harvest-
ing from the growth surface and centrifuging at 300 ×g. 
The supernatant was discarded and the cells were resus-
pended in flow cytometry stain buffer (R&D Systems, UK). 
A panel of mouse anti-human monoclonal antibodies was 
used to target cell-surface receptors and was prepared 
in accordance with the manufacturer’s instructions. The 
antibodies were based on the panel recommended by 
the International Society for Cellular Therapy (ISCT) [29] 
and included CD73-PE, CD90-PE CD105-PerCP, CD14 
FITC, CD19 FITC CD34-PE-Cy7 CD45-PE-Cy5, and HLA-
DR-FITC (R&D Systems, UK). Cells were incubated with 
the antibody in the dark at room temperature for 30 min. 
Associated isotype controls were also prepared for all 
experimental conditions. A minimum of 103 events were 
recorded for each sample and the data were analysed 
using FlowJo computer software (Treestar Inc, USA).
2.6    Differentiation of hBM-MSCs
The multi-lineage potential of the cells was ascertained 
by inducing the samples post-harvest with the Stem-
Pro Adipogenesis kit, StemPro Chondrogenesis kit and 
StemPro Osteogenesis kit (Life Technologies, UK). The 
media were prepared and used as per the manufacturer’s 
instructions and the differentiation studies were per-
formed as described in [30].
2.7    Harvesting of hBM-MSCs
A detailed overview of the harvesting method and theo-
retical principles are provided in [20], briefly however, the 
harvesting procedure began by allowing the microcarri-
ers to settle after which the medium was aspirated. The 
microcarriers were then washed with 100 mL of Ca2+ and 
Mg2+ free PBS. The washing procedure involved placing 
the spinner flasks on a spinner platform and agitating 
at NJS (30 rpm) for 5 min. The microcarriers were again 
allowed to settle and the excess PBS was aspirated. The 
wash procedure was repeated after which 60 mL trypsin 
(0.25%)/EDTA was added to the spinner flasks and the 
spinner flasks were placed in a humidified CO2 controlled 
incubator for 7  min. During this incubation period, the 
vessels were agitated at 150  rpm to aid detachment 
(please refer to [20] for further details and theoretical 
principles). After incubation, the cells were quenched 
with 70 mL growth medium and vacuum filtered using 
a Steriflip® 60 µm filtration unit (Millipore, UK). The cell 
suspension was then centrifuged at 220 ×g for 5 min and 
resuspended in growth medium. 
2.8    Statistical analysis
Statistical significance was determined by analysis of 
two groups of data using the Mann–Whitney U test and 





Prior to microcarrier expansion, the monolayer prolif-
erative capacity of the hBM-MSCs from the three donors 
(hBM-MSC1, hBM-MSC2, hBM-MSC3) were compared. 
The cells were expanded on tissue culture plastic for three 
passages from passage 3 to passage 5 (the cells’ actual 
passage number), hereafter referred to as passage 1 to 
passage 3 (the experimental passage number). 
Significant differences were observed with respect 
to the viable cell number between hBM-MSC1 and 
hBM-MSC2 (p  <  0.01) and hBM-MSC1 and hBM-MSC3 
(p  <  0.005) for passages 1 and 2, and the difference is 
exacerbated by passage 3 (Fig.  1A). The same trend is 
reflected in the cumulative population doublings, where, 
after three passages, hBM-MSC1 reaches about ten 
cumulative population doublings, hBM-MSC2 reaches 
about eight and hBM-MSC reaches about six (Fig.  1B). 
Similarly, hBM-MSC1 consistently yields a greater num-
ber of cells across the three passages (~3.0 to 4.0 × 106 
cells) in comparison to hBM-MSC2 (2.0 to 2.5 × 106 cells) 
and hBM-MSC3 (1.0 to 2.0  ×  106 cells) (Fig.  1A). In 
addition to this, the metabolite data are indicative of 
greater cell proliferation for hBM-MSC1, where, after 
three passages, the cumulative glucose consumption 
(Fig.  1C) was found to be the highest for hBM-MSC1 
(~12.0 mmol/L), followed by hBM-MSC2 (~11.0 mmol/L) 
and hBM-MSC3 (~8.5  mmol/L). The cumulative lactate 
production (Fig. 1D) for hBM-MSC1 and hBM-MSC2 were 
almost identical (28.53 mmol/L for hBM-MSC1 and 28.50 
for hBM-MSC2) whilst for hBM-MSC3 this was demon-
strably lower (~22.5 mmol/L). The cumulative ammonium 
production (Fig. 1E) followed a similar trend, with hBM-
MSC1 producing the most ammonium (2.53  mmol/L), 
hBM-MSC2 producing 2.25 mmol/L and hBM-MSC3 pro-
ducing hBM-MSC3 2.2 mmol/L. 
The data illustrate the innate biological variation 
between the three donor hBM-MSCs, with hBM-MSC1 
performing better with respect to cell growth than hBM-
MSC2, and hBM-MSC2 performing better than hBM-
MSC3. This variation is reflected in the nutrient consump-
tion and metabolite production, whereby more glucose is 
consumed and more lactate and ammonium produced in 
hBM-MSC1 cultures in comparison to hBM-MSC2 and 
hBM-MSC3. It has been found that in general, cell prolif-
6 © 2015 The Authors. Biotechnology Journal published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
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eration correlates with nutrient consumption and produc-
tion of potentially detrimental by-products such as lactate 
and ammonium [31], which is reflected by the findings 
here. All experimental parameters (i.e. time in culture, 
medium, tissue culture flask, operator etc.) between the 
monolayer cultures were standardized, as such, the varia-
tion in growth kinetics is likely to have arisen due to donor 
variation. 
Based on the findings of the monolayer study, the 
microcarrier screening studies were performed with all 
three donor hBM-MSCs to ascertain whether the donor 
cells would demonstrate better cell proliferation on cer-
tain microcarriers, or whether a separate microcarrier for 
each donor would be needed. Moreover, all donor cells 
were used to identify whether the trend observed in the 
monolayer conditions (i.e. hBM-MSC1 performing better 
with respect to cell proliferation than hBM-MSC2, and 
hBM-MSC2 better than hBM-MSC3) was also observed 




Prior to performing the microcarrier screen, the selection 
criteria for the ‘ideal’ microcarrier for hBM-MSC culture 
were established. This focused on three important attrib-
utes:
1. Level of cell proliferation as determined by viable cell 
number, or appropriate orthogonal measurements (i.e. 
WST-1 and metabolite analysis) relative to the other 
microcarriers. 
Figure 1. Monolayer culture growth kinetics and metabolite concentra-
tions for three donor hBM-MSCs across three passages. Viable cell 
number (A) and cumulative population doublings (B) data for hBM-
MSC1, hBM-MSC2 and hBM-MSC3 when cultured in monolayer for three 
consecutive passages. Cumulative glucose consumption (C), lactate pro-
duction (D) and ammonium production (E) for each donor hBM-MSCs 
across the three passages. Data presented as mean ± standard deviation 
(SD) (n = 4). Significant differences of viable cell numbers and cumulative 
population doublings between hBM-MSC2 and hBM-MSC3 were noted 
with p < 0.05 (*) in comparison to hBM-MSC1.
© 2015 The Authors. Biotechnology Journal published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim 7
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2. Amenability for xeno-free processing.
3. Ability to effectively harvest the cells from the micro-
carriers without any detrimental effect on the cells’ 
immunophenotype or differentiation capacity.
A range of commercially available microcarriers (Table 1) 
were screened initially in static microwell plates to iden-
tify an optimal microcarrier for the culture of hBM-MSCs. 
Duplicate ultra-low attachment plates were prepared 
with each plate containing 13 different microcarriers 
and a control well not containing any microcarrier at all 
(No MC). Microcarriers used were selected on the basis 
of: successful prior use for hBM-MSCs expansion (e.g. 
Cytodex-1, Hillex II and Cultispher G), successful culture 
of other cells types (e.g. in vaccine production using 
CHO) and microcarrier physical and chemical proper-
ties.
Since obtaining viable cell number (Fig. 2C) on micro-
carriers can be difficult to achieve in practise and prone to 
error, glucose and lactate concentrations (Fig. 2A), WST-1 
assay absorbance readings (Fig. 2B) of hBM-MSCs grown 
on different microcarriers were also measured, with the 
former generally correlating well with cell growth [32]. In 
general, it was found that the cell proliferation analyses 
resulted in reproducible data as indicated by the tight 
error bars, with the data from each analytical technique 
corroborating the findings of the other analyses. As 
expected the largest error bars were obtained for the 
viable cell number data (Fig. 2C). 
The data from the control well for hBM-MSC1 dem-
onstrates that cells were unable to attach to the ultra-
low attachment surface and proliferate (Fig.  2A–C and 
Supporting information, Fig. S1I). This data was similar 
Figure 2.  Comparison of microcarriers for hBM-MSC culture in static 
microwell plates. For hBM-MSC1 expansion, the glucose consumption 
and lactate production (A), WST-1 absorbance (B) and viable cell num-
ber (C) for each microcarrier is given. Glucose consumption and lactate 
production for hBM-MSC2 (D) and glucose consumption and lactate 
production for hBM-MSC3 (E). The control condition (No MC) contained 
no microcarriers and no cell attachment was expected as ultra-low attach-
ment plates were used. Data is presented as mean ± standard deviation 
(SD) (n = 8). Significant differences in values were noted with p < 0.05 (*) 
in comparison to the highest respective value for each assay.
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www.biotechnology-journal.com www.biotecvisions.com
Biotechnology
Journal Biotechnol. J. 2016, 11
to that found for the PVA microcarriers (Supporting 
information, Fig.  S1M) where the lactate concentration 
never surpassed the glucose concentration during the 
course of the culture, with the glucose concentration 
being relatively high at ~4.5 mmol/L after 144 h and the 
corresponding lactate concentration being relatively low 
(~1.8 mmol/L). Likewise, the WST-1 absorbance reading 
is similar to the control condition with a value of ~0.45 at 
144 h, whilst no viable cells were detected after 144 h. It 
was therefore decided that these microcarriers would not 
be considered for further investigations. Of the remain-
ing microcarriers, Cultispher-G was also considered to 
have performed poorly since it had a high glucose con-
centration (~3.8  mmol/L), a low lactate concentration 
(~6 mmol/L) and low WST-1 absorbance reading (~0.75) 
at 144 h. However, unlike with PVA, it did allow for the 
attachment and proliferation of hBM-MSCs, albeit at a 
very low value of ~2.5 × 104 cells after 144 h. 
The Hillex microcarriers demonstrated cell prolifera-
tion as identified by the change in metabolite con-
centrations and increasing viable cell number, yielding 
~2.25  ×  105 cells. Nevertheless the WST-1 absorbance 
readings were the lowest throughout the culture and did 
not change at 144  h (Fig.  2B). This anomalous reading 
however is not unexpected given that the Hillex micro-
carriers absorb the phenol red indicator present in the 
DMEM (Supporting information, Fig. S1M). As a result, 
it was not possible to obtain accurate WST-1 absorbance 
readings and the WST-1 data for Hillex were disregarded. 
In general, it was found that for hBM-MSC1, the two 
Corning microcarriers (Enhanced Attachment and Syn-
themax II, Supporting information, Fig.  S1E and S1N, 
respectively) and SoloHill microcarriers (Collagen, FACT, 
Hillex, Plastic, Plastic Plus and ProNectin-F, Supporting 
information, Fig. S1B, S1F, S1G, S1J, S1K and S1L, respec-
tively) were the most effective for cell proliferation, with 
respect to metabolite concentrations, WST-1 absorbance 
readings and viable cell number. 
To ascertain whether the relative performance of 
the microcarriers would differ with different donor cells, 
the investigation was repeated using hBM-MSC2 and 
hBM-MSC3 with the exception that the PVA microcarri-
ers were excluded based on previous poor performance. 
Figures 2D and 2E provide the metabolite concentrations 
for hBM-MSC2 and hBM-MSC3 respectively, which illus-
trate that whilst the effect may not be as pronounced, 
the trend with respect to microcarrier performance is the 
same, with the SoloHill microcarriers (in particular Colla-
gen, FACT, Plastic and ProNectin-F) generally consuming 
more glucose and producing more lactate after 144 h for 
both hBM-MSC2 and hBM-MSC3. 
Interestingly, these data correlate well with the mono-
layer metabolite profiles (Fig. 2A–C) for hBM-MSC1, hBM-
MSC2 and hBM-MSC3, with hBM-MSC1 cultures gener-
ally consuming more glucose and producing more lactate 
in comparison to hBM-MSC2, and likewise hBM-MSC2 
more than that of hBM-MSC3. Given that the nutrient/
metabolite concentrations, as indicated in the earlier part 
of this paper, are a relative measure for cell growth, this 
would suggest hBM-MSC1 cultures yielded more cells 
than hBM-MSC2, and likewise hBM-MSC2 more than 





Whilst the studies conducted in the ultra-low attach-
ment microwell plates provided an indication as to the 
performance of the microcarriers, it was important to 
conduct spinner flask based experiments for microcar-
rier comparison, as this would be more representative of 
how the microcarriers would be employed for hBM-MSC 
growth in practise. In addition to this, static vs. agitated 
conditions were compared, whereby the same concen-
tration of microcarriers and cells were inoculated, the 
only difference being that one set of spinner flasks was 
agitated, whilst the other set was not. HBM-MSCs from 
the three donors were cultured on all microcarriers used 
in Section 3.2 with the exception of the PVA microcar-
riers which were discontinued for the reasons stated 
previously. 
Of particular note is the significant difference between 
the static and agitated culture conditions (Fig.  3). At 
144  h, under static culture conditions, the metabolite 
concentrations for each of the different microcarriers for 
all three donor hBM-MSCs were similar, with glucose 
concentrations ranging between ~2 and 3 mmol/L, and 
lactate between ~2 and 5  mmol/L, demonstrating little 
difference between the microcarriers with respect to met-
abolic activity under static conditions (Fig. 3A–C). This is 
reflected by the viable cell number data (Fig. 3D–F), where 
similar cell numbers were obtained between the micro-
carriers, ranging from ~4 to 9 × 106 cells across the three 
different hBM-MSC lines. However under agitated condi-
tions at 144 h, the glucose concentrations were generally 
below 2.5 mmol/L for most microcarriers and greater than 
5 mmol/L with respect to lactate, with both Plastic and 
Collagen resulting in the lowest glucose concentrations 
and highest lactate concentrations (Fig. 3A–C). Similarly, 
the viable cell numbers were generally >8 × 106 cells, with 
both Plastic and Collagen resulting in the greatest num-
ber of viable cells in the agitated conditions for all three 
hBM-MSCs (Fig. 3D–F).
In all cases for the static and agitated spinner flask 
cultures, the percentage of initial cell adhesion was found 
to be ~55% based on identification of non-attached cells 
from 1 mL supernatant samples obtained 1 h post-seed-
ing. The percentage of recovered cells, in all cases, was 
found to be >95% as determined by pre-harvest samples 
and post-harvest recovery. Unfortunately, it was not pos-
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sible to quantify the attachment efficiency for the micro-
wells because of the limited sample volume available in 
them, i.e. taking a 1 mL supernatant sample as required 
for measurement from a 2 mL culture volume would make 
the experiment valueless.
Although the respective glucose and lactate con-
centrations values are lower in the static spinner flask 
compared to the static micro-well plates (Fig.  2A and 
3A), importantly, the general trend of microcarrier perfor-
mance for the donor hBM-MSCs is similar, with the same 
set of microcarriers (Collagen, Plastic, ProNectin-F) per-
forming better with respect to proliferation (Fig. 2 and 3). 
It is likely this disparity in the concentration values 
between the static spinner flasks and the micro-well 
plates is due to inferior attachment in the former result-
ing in delayed proliferation. Although the concentration 
of microcarriers was proportional to the volume of culture 
medium, the two culture platforms had different geome-
tries and sizes. As a result, the microcarriers in the micro-
well plate covered a greater proportion of the base than in 
Figure 3.  Comparison of static and agitated conditions for hBM-MSC microcarrier culture, and a comparison of different microcarriers in 100 mL spinner 
flasks. Glucose consumption and lactate production for hBM-MSC1 (A), hBM-MSC2 (B) and hBM-MSC3 (C). Viable cell number for hBM-MSC1 (D),  
hBM-MSC2 (E) and hBM-MSC3 (F). Data is presented as mean ± standard deviation (SD) (n = 4). Significant differences in values were noted with  
p < 0.05 (*) in comparison to the highest respective value.
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the spinner flask, to which the cells would fall under the 
action of gravity, thus resulting in a better attachment. In 
addition, the distance that the cells have to settle in the 
micro-wells is less than in the spinner flask. As explained 
above, it was not possible to quantify the attachment 
efficiency for the micro-wells.
In the case of the agitated spinner flasks however, once 
agitation is initiated, cell proliferative activity improves as 
a result of improved mass transfer and surface area avail-
ability (as the entire surface area of the microcarrier is 
now exposed rather than just the top layer as it the case 
when microcarriers are left static).
The specific glucose consumption and specific lactate 
production rates were determined for each microcar-
rier and each hBM-MSC line under agitated conditions 
(Fig.  4). Unlike the glucose and lactate concentrations 
and viable cell number, it was not possible to differentiate 
significantly between the microcarriers on the basis of the 
specific metabolite flux. Generally, the specific glucose 
consumption rate was found to be ~9 to 10 pmol/cell/day 
and the specific lactate production rate ranged between 
17 and 20 pmol/cell/day. There were notable exceptions, 
for example, the specific glucose consumption rates for 
MicroHex and Cultispher-G were consistently at ~7 pmol/
cell/day for each hBM-MSC, which is believed to be 
related predominantly to the proliferative rate in this 
instance. A similar trend is found with the specific lactate 
production rate where MicroHex and Cultispher-G have 
the lowest lactate production rates.
Another key finding from this study was that for all 
three donor hBM-MSCs, the relative microcarrier perfor-
mance was equivalent, with the same set of microcarri-
ers performing better with respect to nutrient/metabolite 
consumption and production (e.g. Collagen, Plastic and 
ProNectin-F), whilst the microcarriers that did not per-
form well with one donor hBM-MSC generally tended 
not to perform well with the other donor hBM-MSCs 
(e.g. Cultispher-G, Cytodex-3 and MicroHex). Moreover, 
the relative performance of the microcarriers mirrored 
the findings of the microwell plate study and similarly, 
the hBM-MSC1 cultures outperform the hBM-MSC2 and 
hBM-MSC3 cultures with respect to the lactate produc-
tion, glucose consumption and by extension, the cell 
growth. 
Based on the findings of the screening studies, and 
the selection criteria outlined previously, it was decided 
that the SoloHill Plastic microcarrier was the most suit-
able given the propensity of the hBM-MSCs to proliferate 
on the microcarrier and the fact that these microcarriers 
(unlike SoloHill Collagen) were amenable for xeno-free 
processing as they are free from any animal-derived com-
ponents. The final aspect of the selection criteria was to 
determine whether the cells could be harvested from the 
Plastic microcarriers without adversely affecting their dif-
ferentiation capacity or immunophenotype.
3.4     hBM-MSCs retain key identity and functionality 
markers after microcarrier harvest
Spinner flask cultures with cells growing on Plastic 
microcarriers were harvested as described previously 
(Section 2.7). This involved a combination of incubating 
the cells with a dissociation reagent (in this case trypsin) 
and increasing the agitation speed five-fold (in compari-
son to the agitation speed used for culturing, NJS). Once 
detached, the cells were separated from the microcarriers 
by filtration and harvested cells were characterized with 
respect to their differentiation capacity (Supporting infor-
mation, Fig. S2A–C) and immunophenotype (Supporting 
information, Fig. S2D). It was found the cells were able to 
retain their ability to differentiate toward the osteogenic 
(Supporting information, Fig. S2A), adipogenic (Support-
ing information, Fig. S2B) and chondrogenic (Supporting 
information, Fig. S2C) lineages as determined by the Von 
Kossa/Alkaline Phosphatase, Oil Red O and Alcian Blue 
staining respectively. Similarly, the cells were analysed 
prior to spinner flask inoculation and post-spinner flask 
harvest by flow cytometry for four positive markers (CD29, 
CD73, CD90 and CD105) and five negative markers (CD14, 
CD19, CD34, CD45, HLA-DR), and in both cases, the cell 
expression was >95% for the positive markers and <2% 
for the negative markers. These assays demonstrate the 
harvested cells were in accordance with the ISCT criteria 
for hMSCs [29] and that the harvest process had little or no 
apparent effect on the cells. This fulfilled the final criterion 
for successful microcarrier selection that we had outlined, 
i.e. the ability to effectively harvest the hBM-MSCs from 
the microcarrier.
The harvesting of the cells with the recently devel-
oped enzymatic-agitation protocol from the microcarrier 
with best perceived characteristics (xeno-free structure 
and good growth) was also successful. This result is also 
Figure 4.  Specific glucose consumption and lactate production rates for 
each microcarrier and each hBM-MSC lines in the agitated spinner flasks. 
Data is presented as mean ± standard deviation (SD) (n = 4).
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very encouraging because harvesting is an essential part 
of the production process for allogeneic therapies. Never-
theless, more work is required to establish the universality 




The selection of the most appropriate microcarrier is a 
critical component of any microcarrier-based cell therapy 
production process, yet there is little in the way of system-
atically evaluating microcarriers, or what the criteria for 
selecting a microcarrier should be.
As mentioned previously Schop et al. [23] and Kehoe 
et al. [24] have undertaken a microcarrier screen, yet both 
studies only investigated the growth of one hBM-MSC 
line and in the case of Schop et al. study, the assessment 
was based on cell attachment and proliferation over an 
18-hour period [23]. Hupfeld et al. state that their selection 
of Cytodex-1 for the culture of umbilical cord and amniotic 
membrane hMSCs was based on a microcarrier screen of 
six microcarriers and was based on microscopic observa-
tion, metabolic activity and expansion ratios [33]. How-
ever the data are not shown nor referenced; nevertheless, 
they report that Cytodex-1 was selected on the basis of 
expansion, which is different to what has been found here 
[33]. Whilst it is not possible to compare the data directly, 
it is likely that differences found between these studies 
to be predominantly related to the source of hMSCs used 
(umbilical cord and amniotic membrane). 
Li et al. (2015) selected Cultispher-G due to the 
microcarrier’smacroporous and biodegradable properties 
for the culture of human hair follicle-derived MSCs [34]. 
Unlike the findings here, they report successful growth of 
the human follicle-derived MSCs on Cultispher-G. How-
ever they do not report the growth of the follicle-derived 
MSCs on other microcarriers [34]. The study we have 
conducted here would allow for a swift and robust assess-
ment of multiple microcarriers simultaneously and enable 
researchers and cell therapy developers to identify the 
optimal microcarrier with respect to proliferation.
The microcarrier screening investigations demon-
strated that whilst hBM-MSC growth was observed on 
all but one of the microcarriers, some were clearly more 
amenable for hBM-MSC growth than others. This was 
also found by Goh et al. (2013) who compared the prolif-
erative capacity of four microcarriers (Plastic, Cytodex-1, 
Cytodex-3 and Cultispher G) for the expansion of human 
foetal MSCs [35]. They also found that Cultispher-G was 
poorest performing microcarrier investigated with a sig-
nificant difference in cell density in comparison to the 
other microcarriers. The authors reported that Plastic 
and Cytodex-3 were the joint best performing microcarri-
ers with an overall cell density of 6.8 × 105 cells/mL after 
12 days of culture whilst Cytodex-1 resulted in a density 
of 6.5 × 105 cells/mL. The authors selected Cytodex-3 as 
their microcarrier of choice due to the concern that the 
Plastic microcarriers resulted in a greater level of aggre-
gation which was suggested to result in a reduction in 
osteogenic potential.
Similarly, work conducted by Dos Santos et al. sought 
to, and successfully demonstrated that the SoloHill Plas-
tic microcarriers were equally as efficient for hBM-MSC 
growth as the Cultispher-S microcarriers that were used 
by the group previously [36]. The reason for the change in 
microcarrier was due to the animal-derived gelatin com-
ponent on the Cultispher-S microcarrier [36]. 
Cultispher-G, oft-cited in the literature [25, 37, 38], 
was one of the poorest performing microcarriers in both 
the microwell and spinner flask studies, highlighting that 
it is important to consider a range of microcarriers before 
establishing a process based on a specific microcarrier. 
MicroHex (hexagonally-flat shaped with a thickness of 
only 25 µm), is a microcarrier whose unique selling point 
is that the carrier is made from the same material as 
Nunc’s successful tissue culture plasticware (T-flasks and 
multi-well plates). Yet, surprisingly, it too did not perform 
well in the screening studies. MicroHex was also part of 
the microcarrier screen employed by Hupfeld et al. (2014) 
[33]. However, they do not report the relative performance 
of the microcarriers. Given that hBM-MSCs readily attach 
and proliferate on the same material when cultured in a 
T-flask, one would have assumed that this would be one 
of the best microcarriers for hBM-MSCs. However, as this 
was not the case here, it suggests that other physical 
properties of the microcarrier such as the shape, size and 
density and not only the material of construction are also 
likely to play an important role for successful cell growth. 
Another notable finding from these studies is the wide 
difference in hBM-MSC growth on the different micro-
carriers. It may have been assumed that as a number of 
these microcarriers have been employed for the success-
ful growth of hBM-MSCs [17], the performance of these 
microcarriers with respect to cell growth would be similar. 
Yet the data in Fig.  2–4, in addition to similar studies 
reported in the literature [23, 24, 35] would suggest oth-
erwise and again highlight the fundamental importance 
of microcarrier selection as part of the hBM-MSC-micro-
carrier optimization process. With such a range of micro-
carrier performance, it may be argued that the primary 
consideration for hBM-MSC microcarrier culture should 
be the type of microcarrier employed.
With respect to the metabolic performance of the 
hBM-MSCs, the trends between cell lines were similar 
for each microcarrier. The specific glucose consumption 
and lactate production values found in this study (Fig. 4) 
are generally in line with those reported elsewhere. Dos 
Santos et al. reported specific glucose consumption val-
ues ranging between 5 and 15 pmol/cell/day, averaging at 
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~10 pmol/cell/day and specific lactate production values 
ranging between 20 and 25  pmol/cell/day [36]. Similar 
findings were presented by Schop et al. and appear to be 
indicative of hBM-MSC microcarrier culture [23]. Impor-
tantly, neither the glucose nor the lactate concentrations 
reached values which would inhibit cell proliferation.
In monolayer culture, MSCs are typically cultured 
on standard tissue culture plastic which is negatively 
charged (e.g. Nunclon Delta Surface and Corning Cell-
BIND) but many culture dishes with positively charged 
surfaces are now available as this is believed to enhance 
cell attachment (e.g. Nunc and Corning Poly-D-lysine 
surfaces). Indeed, it has been demonstrated by Chun et 
al. that positively charged poly(lactic-co-glycolic acid) 
(PLGA) particles demonstrated greater levels of attach-
ment and proliferation compared to negatively charged 
ones [39]. This is in contrast to the data shown here 
and that of Kehoe et al. [24] where the neutrally charged 
Plastic and Collagen outperform their positively charged 
equivalents (Plastic Plus and FACT respectively, Table 1) 
with respect to cell growth. This emphasizes the com-
plexity of the interaction between cells and material 
and that surface charge alone does not determine the 
capacity of a material to support cell attachment and/or 
growth. Indeed, surface charge density, hydrophobicity 
and topography have all been shown to impact cell adhe-
sion, proliferation and even phenotype [40–43]. 
Interestingly, in this study, the SoloHill microcarri-
ers, in particular Plastic, Collagen, FACT and ProNectin 
F (Table  1), which all have the same polystyrene base 
but different coatings and charges, performed best with 
respect to cell growth in both the static/agitated condi-
tions as well as the microwell plate studies. Notably, Cyto-
dex-3 and the SoloHill Collagen microcarriers which have 
the same biological coating but contain a different core 
material performed very differently. Our data therefore 
suggest that the fundamental nature of the particle (i.e. 
shape, size and density of the bead or mechanical stiff-
ness of the base material) may also be a key factor in pro-
viding a conducive surface for cell adhesion and growth. 
Indeed, the stiffness of a surface matrix has previously 
been shown to affect MSC proliferation rate [42].
4.2     Significant improvement in hBM-MSC yield in 
agitated cultures compared to static conditions
Of the major findings of this study, most notable is the 
effect of agitation on hBM-MSC microcarrier culture 
(Fig. 3) and the wider implications this has on cell therapy 
bioprocessing. There is a significant difference when 
comparing the metabolite concentration and viable cell 
number for both the static and agitated cultures. More 
glucose is consumed and more lactate produced under 
agitated conditions in all cases, demonstrating that the 
cells are more metabolically active (and presumably more 
proliferative) in an agitated environment. This is not 
unexpected as it is widely acknowledged that agitation 
generates a homogenous physical and chemical envi-
ronment by improving mass transfer and reducing con-
centration gradients [18]. In addition to this, an agitated 
environment exposes the entirety of the microcarrier 
surface area to the cells, whereas static conditions do not. 
Indeed, one of the reasons to employ a microcarrier-based 
culture is to attain the benefits of a well-mixed, agitated 
system [21, 44].
Whilst the difference between static and agitated con-
ditions for microcarrier culture is significant, it is unlikely 
that a microcarrier-based process will ever be conducted 
under static conditions. What this does illustrate however 
is the importance of a well-mixed system for improv-
ing cell yields. Even if a process is to be scaled via a 
monolayer expansion platform, efforts should be made 
to provide a mixed system and promote mass transfer. A 
prime example of this for monolayer culture are the roller 
bottle manufacturing platforms which are similar in prin-
ciple to a T-flask based process. However these have the 
added advantage of improved mass transfer via a rolling 
mechanism.
4.3    Key implications for cell therapy bioprocessing
A key finding from this study, and one that has potentially 
significant bioprocessing implications, is that irrespec-
tive of how the hBM-MSCs from different donors compare 
with each other with respect to growth, there is a gen-
eral trend as to microcarriers which appear to promote 
favorable growth. For example, despite the differences 
in growth kinetics between hBM-MSC1, hBM-MSC2 
and hBM-MSC3, they all performed better on Collagen, 
Plastic and ProNectin F in comparison to other microcar-
riers. It therefore suggests that once a microcarrier has 
been selected following a rigorous screening process as 
developed in this study, a process can be built around that 
particular microcarrier and there may not be the need to 
develop an entirely new process should the original donor 
cell bank be depleted and a new donor cell bank intro-
duced. Productivity may be affected, but this is not due to 
the microcarrier and this can be minimized for an alloge-
neic process by sourcing donor cells similar to the original 
cells. Similarly, the fact that the donor cell growth kinetic 
performance relative to one another was maintained from 
monolayer through to agitated microcarrier culture sug-
gests that donor cell screening for microcarrier culture 
needn’t necessarily take place on microcarriers, but 
potentially, a relatively cheaper and more routine mon-
olayer culture may suffice, thereby allowing for significant 
cost, resource and time savings. Finally, it is also worth 
noting that the relative performance of the microcarri-
ers with the small-scale, static microwell plate studies 
was identical to the findings in the larger-scale agitated 
spinner flasks, again suggesting that a relatively cheaper 
and smaller microwell screening experiment may suffice 
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as a high-throughput microcarrier screening process, 
particularly when comparing the performance of multiple 
commercially available or in-house produced microcar-
riers and when utilizing expensive media and reagents.
5    Concluding remarks
Employing the most appropriate microcarrier for hBM-
MSC expansion is a critical component of a microcarrier-
expansion process. This study developed a systematic 
method for selecting an appropriate microcarrier for the 
culture of hBM-MSCs. Findings from this investigation 
suggest that whilst an agitated bioreactor comparison 
study would be definitive, microwell screening study 
may be sufficient for high-throughput comparison of mul-
tiple microcarriers. Following an evaluation of thirteen 
commercially available microcarriers the SoloHill Plastic 
microcarrier was selected as the optimal microcarrier 
for hBM-MSC expansion based on the following criteria: 
(i) extent of cell proliferation on the microcarrier; (ii) ame-
nability for xeno-free processing; and (iii) the ability to 
effectively harvest the cells from the microcarrier without 
any detrimental effect on cellular immunophenotype and 
differentiation capacity.
The relative performance of microcarriers was identi-
cal for each of the donor hBM-MSCs, which has potentially 
significant implications for cell therapy bioprocessing as 
it would suggest that for an allogeneic process, a process 
will not need to be revalidated with a new microcarrier if 
a donor cell bank is exhausted. Similarly, it was demon-
strated that agitated conditions were significantly better 
than static conditions, reinforcing the need for providing 
a homogenous culture environment irrespective of the 
culture platform. 
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